Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $763.87 | 14 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $226.29 | 5 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $142.51 | 2 | $0 (2020) |
| Alimera Sciences, Inc. | $94.36 | 1 | $0 (2019) |
| Allergan Inc. | $81.82 | 1 | $0 (2018) |
| AbbVie, Inc. | $76.28 | 1 | $0 (2018) |
| Genentech USA, Inc. | $75.62 | 1 | $0 (2018) |
| Genentech, Inc. | $48.82 | 2 | $0 (2022) |
| Spark Therapeutics, Inc. | $18.17 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $27.40 | 1 | Genentech, Inc. ($27.40) |
| 2021 | $21.42 | 1 | Genentech, Inc. ($21.42) |
| 2020 | $76.23 | 1 | Regeneron Healthcare Solutions, Inc. ($76.23) |
| 2019 | $380.43 | 7 | Novartis Pharmaceuticals Corporation ($201.62) |
| 2018 | $258.39 | 4 | Allergan Inc. ($81.82) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/15/2022 | Genentech, Inc. | SUSVIMO (Drug), VABYSMO | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/21/2021 | Genentech, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: Ophthalmology | ||||||
| 02/27/2020 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $76.23 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/09/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $85.08 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/23/2019 | Spark Therapeutics, Inc. | LUXTURNA (Biological) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: OCULAR | ||||||
| 08/05/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $17.08 | General |
| 06/26/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $76.53 | General |
| 04/09/2019 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $66.28 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/19/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $22.93 | General |
| 01/14/2019 | Alimera Sciences, Inc. | Iluvien (Drug) | Food and Beverage | Cash or cash equivalent | $94.36 | General |
| Category: Ophthalmology | ||||||
| 11/12/2018 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $75.62 | General |
| Category: Ophthalmology | ||||||
| 09/13/2018 | Novartis Pharmaceuticals Corporation | BROLUCIZUMAB (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| 09/05/2018 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $76.28 | General |
| Category: Immunology | ||||||
| 08/09/2018 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $81.82 | General |
| Category: RETINA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 947 | 4,104 | $1.1M | $509,292 |
| 2022 | 17 | 2,601 | 8,593 | $3.6M | $1.8M |
| 2021 | 18 | 2,422 | 7,559 | $4.2M | $2.1M |
| 2020 | 19 | 2,101 | 6,549 | $3.6M | $1.8M |
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 138 | 490 | $612,500 | $341,266 | 55.7% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 28 | 2,400 | $137,016 | $67,577 | 49.3% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 30 | 229 | $114,500 | $42,239 | 36.9% |
| 67028 | Injection of drug into eye | Office | 2023 | 265 | 394 | $119,250 | $29,720 | 24.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 137 | 149 | $24,734 | $11,551 | 46.7% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 84 | 131 | $38,430 | $7,884 | 20.5% |
| 92134 | Imaging of retina | Office | 2023 | 198 | 241 | $16,800 | $5,812 | 34.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 56 | 59 | $6,667 | $2,213 | 33.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $2,442 | $1,031 | 42.2% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 309 | 1,568 | $2.0M | $1.1M | 57.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 106 | 1,257 | $628,500 | $277,186 | 44.1% |
| 67028 | Injection of drug into eye | Office | 2022 | 605 | 1,379 | $403,500 | $120,149 | 29.8% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 22 | 1,980 | $113,038 | $59,086 | 52.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 349 | 469 | $77,854 | $37,903 | 48.7% |
| J7999 | Compounded drug, not otherwise classified | Office | 2022 | 216 | 465 | $132,710 | $30,481 | 23.0% |
| 92134 | Imaging of retina | Office | 2022 | 526 | 916 | $63,840 | $24,953 | 39.1% |
| 67113 | Complex repair of detached retina and drainage of eye fluid between lens and retina | Facility | 2022 | 16 | 17 | $45,050 | $16,790 | 37.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 195 | 263 | $29,719 | $16,636 | 56.0% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2022 | 40 | 56 | $94,500 | $14,958 | 15.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 102 | 102 | $22,644 | $11,268 | 49.8% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2022 | 11 | 11 | $25,080 | $9,358 | 37.3% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2022 | 21 | 21 | $14,080 | $5,014 | 35.6% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 36 | 36 | $7,020 | $2,764 | 39.4% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2022 | 16 | 16 | $17,510 | $2,568 | 14.7% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2022 | 19 | 25 | $4,225 | $828.10 | 19.6% |
About Dr. Frank Wyant, D.O
Dr. Frank Wyant, D.O is a Ophthalmology healthcare provider based in Albuquerque, New Mexico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1497740989.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Frank Wyant, D.O has received a total of $763.87 in payments from pharmaceutical and medical device companies, with $27.40 received in 2022. These payments were reported across 14 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($763.87).
As a Medicare-enrolled provider, Wyant has provided services to 8,071 Medicare beneficiaries, totaling 26,805 services with total Medicare billing of $6.2M. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Practice Information
- Specialty Ophthalmology
- Location Albuquerque, NM
- Active Since 09/12/2005
- Last Updated 04/25/2008
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1497740989
Products in Payments
- EYLEA (Biological) $142.51
- Lucentis (Biological) $97.04
- Iluvien (Drug) $94.36
- BEOVU (Drug) $85.08
- OZURDEX (Drug) $81.82
- Humira (Biological) $76.28
- SUSVIMO (Drug) $27.40
- BROLUCIZUMAB (Drug) $24.67
- LUXTURNA (Biological) $18.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Albuquerque
John Pitcher, M.d, M.D
Ophthalmology — Payments: $351,399
Robert Melendez, M.d, M.D
Ophthalmology — Payments: $260,758
Dr. Christopher Roybal, M.d, M.D
Ophthalmology — Payments: $53,047
Stephen Coleman, Md, MD
Ophthalmology — Payments: $15,456
Rachel Davis
Ophthalmology — Payments: $13,286
Arup Das, Md, MD
Ophthalmology — Payments: $11,111